Table 3 Frequency of Adverse Events for First-Line AML Therapies [Source: [11]]
Adverse event, n (%) | GO + DA (N = 131) | DA (N = 137) |
|---|---|---|
Skin toxicity | 14 (10.7) | 23 (16.8) |
Mucosal toxicity | 21 (16.0) | 9 (6.6) |
Pain | 19 (14.5) | 5 (3.6) |
Nausea, vomiting e diarrhea | 22 (16.8) | 14 (10.2) |
Pulmonary toxicity | 17 (13.0) | 19 (13.9) |
Cardiac rhythm disorder | 5 (3.8) | 4 (2.9) |
Other cardiac toxicity | 6 (4.6) | 5 (3.6) |
Central neurological toxicity | 8 (6.1) | 4 (2.9) |
Peripheral neurological toxicity | 4 (3.1) | 2 (1.5) |
Infections | 102 (77.9) | 106 (77.4) |
Hemorrhage | 30 (22.9) | 13 (9.5) |
Veno-occlusive disease | 5 (3.8) | 2 (1.5) |